The Long-term Effect Of Sacubitril-Valsartan On Ventricular Arrhythmia Burden Detected By Implantable Cardioverter Defibrillator Among Ischemic Cardiomyopathy Patients With Reduced Ejection Fraction

Konstantinos Polymeropoulos,Alexia Stavrati,Stellina Al-Kajed,George Tsinopoulos,Polydoros Lazaridis,Vassilios Tzalamouras,Stylianos Paraskevaidis

DOI: https://doi.org/10.1016/j.cardfail.2023.10.363

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Sacubitril-Valsartan (SV) reduced the risk of sudden cardiac death (SCD) among patients with heart failure and reduced ejection fraction (HFrEF), according to recent data. However, there are few and conflicting long-term data about the impact of SV on ventricular arrhythmias on the clinical context of ischemic cardiomyopathy (ICM) and implantable cardioverter defibrillator (ICD). Purpose To determine the long-term effect of SV on ventricular arrhythmia burden in ICD recipients suffering from ICM with reduced ejection fraction (EF), before and after SV introduction. Methods 110 patients with ICM and ICD initiated treatment with SV, 10 patients died or lost and 8 had SV withdrawn due to intolerance. We studied 92 patients, (mean age 68±9 years; 62 male), with ICM, left ventricular ejection fraction (LVEF) ≤35% and New York Heart Association class ≥ΙΙ, implanted with an ICD, for a 12-month follow-up, before and after SV initiation. Primary prevention SCD was the main indication (55%) for ICD implantation. All detected ventricular arrhythmias (sustained ventricular tachycardia-VT, ventricular fibrillation-VF and non-sustained ventricular tachycardia-NS-VT) were thoroughly reviewed and analyzed. Results All patients received the highest tolerated doses of medications for HFrEF. There was no difference between groups concerning the dose of b-blocker or aldosterone antagonist. LVEF was increased (27±5% vs 33±6%, p<0.001) and systolic blood pressure decreased (125±12% vs 116±11%, p<0.001) after SV treatment. However, ventricular arrhythmia burden significantly increased over 12 months of follow-up and it was consistent for all types of ventricular arrhythmias (ventricular tachycardia from 6.5% to 16.3%, ventricular fibrillation from 3.2% to 13.1% and non-sustained ventricular tachycardia from 9.8% to 30.4%). Several explanations may apply. A significant number of our patients (46%) did not manage to achieve the goal SV dose of 97/103 mg twice daily. Also, 45% had a history of ventricular arrhythmias, already posed a high baseline arrhythmic risk. Some of these patients had extensive myocardial infarction scars, so the beneficial effect of SV treatment on fibrosis could be ambiguous. Conclusions SV did not reduce ventricular arrhythmia burden in our cohort of ICD recipients suffering from ischemic HFrEF over 12 months of treatment, although EF was increased.

cardiac & cardiovascular systems